Phase II Study of Bevacizumab Plus CHOP [cyclophosphamide, doxorubicin, vincristine, prednisolone]-Rituximab in Patients With Untreated Mantle Cell Lymphoma (NHL).

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Bevacizumab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
Indications Mantle-cell lymphoma
Focus Adverse reactions

15 Sep 2017 Status changed from active, no longer recruiting to completed.
18 Apr 2011 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov.
18 Apr 2011 Planned End Date changed from 1 Nov 2010 to 1 Jul 2011, according to ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com